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Human cytomegalovirus (HCMV) is a significant
cause of morbidity and mortality in organ transplant
recipients. The use of granulocyte-colony stimulating
factor (G-CSF)-mobilized stem cells from HCMV
seropositive donors is suggested to double the
risk of late-onset HCMV disease and chronic graft-
versus-host disease in recipients when compared
to conventional bone marrow transplantation with
HCMV seropositive donors, although the etiology of
the increased risk is unknown. To understand mech-
anisms of HCMV transmission in patients receiving
G-CSF-mobilized blood products, we generated a
NOD-scid IL2Rgc
null-humanized mouse model in
which HCMV establishes latent infection in human
hematopoietic cells. In this model, G-CSF induces
the reactivation of latent HCMV inmonocytes/macro-
phages that have migrated into organ tissues. In
addition to establishing a humanized mouse model
for systemic and latent HCMV infection, these results
suggest that the use of G-CSF mobilized blood
products from seropositive donors pose an elevated
risk for HCMV transmission to recipients.
INTRODUCTION
Bone marrow-derived myeloid precursor cells are considered
to be the latent source of HCMV in seropositive hosts. The differ-
entiation of these latently infected myeloid precursors into
migrating macrophages is the proposed mechanism for organ
dissemination and viral reactivation followed by subsequent
disease (Sinclair and Sissons, 2006; Smith et al., 2004a,
2004b, 2007; So¨derberg-Naucle´r et al., 1997). Consistent with
the idea that myeloid precursors are the site of HCMV latency,
reactivation of HCMV following allogeneic stem cell transplanta-284 Cell Host & Microbe 8, 284–291, September 16, 2010 ª2010 Elstion (SCT) in the absence of preventative measures occurs in
69% of HCMV-seropositive recipients and 36% of HCMV-sero-
negative recipients of cells from seropositive donors (Meyers
et al., 1986). Although pre-emptive drug treatment reduces the
risk of HCMV morbidity and mortality in SCT recipients, these
therapies are associated with a higher frequency of late onset
HCMV disease and a mortality rate of up to 50% (Asano-Mori
et al., 2008; Castagnola et al., 2004).
Currently, G-CSF is commonly used to mobilize stem cells in
donors for peripheral blood stem cell transplantation (PBSCT)
(Ko¨rbling and Anderlini, 2001). Considerable controversy exists
regarding the use of peripheral blood stem cells derived from
G-CSF-mobilized donors and the risk of late-onset HCMV
disease in transplant recipients. In particular, several studies
indicate that the use of G-CSF-mobilized blood products for
PBSCT doubles the risk for both late-onset HCMV disease and
chronic graft-versus-host disease when compared to bone
marrow transplantation (Anderson et al., 2003; Blaise et al.,
2000; Champlin et al., 2000; Kalayoglu-Besxisxik et al., 1998).
The etiology of the increased risk of late-onset HCMV disease
associated with PBSCT is unknown. Another controversy
concerning HCMV and G-CSF-mobilized blood products exists
with conflicting reports on the impact of donor HCMV sero-
status and the development of HCMV disease in patients
receiving G-CSF-mobilized granulocyte transfusions to treat
prolonged neutropenia (Meyer-Koenig et al., 2004; Narvios
et al., 2002; Nichols et al., 2002; Vij et al., 2003). The controver-
sies in clinical studies surrounding HCMV and G-CSF-mobilized
blood products likely exist due to differences in screening
donors for HCMV, monitoring HCMV viral load in recipients,
and prophylactic or pre-emptive HCMV treatment strategies,
thus underscoring a need for animal studies evaluating the
effects of G-CSF on HCMV transmission.
Since HCMV replication is strictly limited to cells of human
origin, an animal model has not been available to examine
mechanisms of HCMV latency and reactivation. Previous severe
combined immunodeficient (SCID) mouse models for HCMV
have utilized small human tissue implants, where the virus
replicates locally and does not spread beyond the implantedevier Inc.






post-G-CSF Bone marrow Spleen Liver Kidney Lung SMG Bladder
Engrafted mock
+ G-CSF
0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
Nonengrafted HCMV
+ G-CSF
0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
Engrafted HCMV
 G-CSF
0/3 NA 3/3 2/3 0/3 1/3 0/3 0/3 0/3
Engrafted HCMV
+ G-CSF
0/3 3/3 3/3 3/3 3/3 3/3 2/3 1/3 1/3
CD34+ HSC-engrafted NOD-scid IL2Rgc
null mice were mock-infected or HCMV-infected at 4 weeks postengraftment. At 4 weeks postinfection,
engrafted mice were administered G-CSF by osmotic pump for 7 days and sacrificed (engrafted mock + G-CSF; engrafted HCMV + G-CSF). Three
mice did not receive G-CSF treatment and were sacrificed at 5 weeks postinfection (engrafted HCMV – G-CSF). As a negative control, nonengrafted
mice were HCMV infected, administered G-CSF for 7 days at 4 weeks postinfection, and sacrificed (nonengrafted HCMV + G-CSF). Peripheral blood
mononuclear cells, bonemarrowmononuclear cells, and organ tissue was tested for the presence or absence of HCMV genomic DNA by nested PCR.
Shown are the ratios of mice testing positive for HCMV DNA out of total mice tested. PBMC Pre-G-CSF and PBMC post-G-SCF indicate peripheral
blood mononuclear cells tested before and after mobilization, respectively. NA, not applicable; PBMC, peripheral blood mononuclear cells; SMG,
submandibular salivary gland.
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G-CSF Reactivates HCMV in Humanized Micetissue (Bidanset et al., 2001; Mocarski et al., 1993). Due to the
absence of human bonemarrow-derivedmyeloid precursor cells
and mature myeloid lineage cells, SCID mice with human
implants do not support systemic infection nor do these mice
develop viral latency (Bidanset et al., 2004; Mocarski et al.,
1993). Nonobese diabetic (NOD)/SCID mice can be stably
engrafted with human (hu)CD34+ hematopoietic stem cells
(HSCs) following sublethal irradiation due to a lack of an adaptive
immune system and innate immunity defects. In this xenograft
model, huCD34+ HSCs self-renew in the BM and provide long-
term repopulation of mice with multilineage human myeloid
and lymphoid cell populations (Legrand et al., 2006). NOD/
SCID mice engrafted with huCD34+ HSCs have been shown to
be useful tools to examine human viruses that involve hemato-
poietic cells in their life cycles (Islas-Ohlmayer et al., 2004; Sun
et al., 2007; Wu et al., 2006). Therefore, we hypothesized that
huCD34+-engrafted NOD/SCID mice would support a systemic
HCMV infection and HCMV latency due to the critical role of
myeloid progenitors, monocytes, and macrophages in HCMV
latency, reactivation, and spread.
RESULTS
G-CSF Promotes HCMV Dissemination to Organ Tissues
in huCD34+-Engrafted NOD-scid/IL2Rgc
null Mice
For the development of a HCMV mouse model, we utilized
NOD-scid IL2Rgc
null mice, which have higher huCD34+ stem
cell engraftment potential compared to NOD/SCID mice due
to additional defects in innate immunity resulting from IL2Rgc
deficiency (Ito et al., 2002; Legrand et al., 2006). In testing
multiple routes of HCMV infection, we found that intraperitoneal
(IP) injection of HCMV-infected human fibroblasts was the only
means of infection leading to detectable viral DNA in organ
tissues by nested PCR (data not shown). To determine the organ
distribution of HCMV, huCD34+-engrafted NOD-scid IL2Rgc
null
mice were injected IP with HCMV-infected fibroblasts and
sacrificed at 4 weeks postinfection. Nested PCR analysis
revealed that engrafted, HCMV-infected mice had detectableCell Host &HCMV DNA in the bone marrow (BM; 3/3 mice), spleen
(2/3 mice), and kidneys (1/3 mice; Table 1). Viral DNA was not
detected in any organ tissue tested from huCD34+ engrafted,
mock-infected mice or nonengrafted, HCMV-infected mice
(Table 1), indicating that the stem cell source was not contami-
nated with HCMV and that HCMV did not persist in murine cells,
respectively.
In vitro studies implicate monocytes as the cells responsible
for hematogenous dissemination of HCMV to organ tissue
(Bentz et al., 2006; Smith et al., 2004a, 2007; So¨derberg-Naucle´r
et al., 2001). Therefore, we hypothesized that G-CSF mobiliza-
tion of myeloid cells from the BM would increase the distribution
and frequency of organ tissue positive for HCMV DNA. To test
this hypothesis, huCD34+-engrafted mice were administered
G-CSF by osmotic pump for 7 days at 4 weeks postinfection.
To assess the efficacy of G-CSF treatment, peripheral blood
mononuclear cells (PBMCs) were analyzed. Although the rela-
tive ratios of mouse and human hematopoietic cells (CD45+)
remained similar to that observed in premobilized mice (Fig-
ure 1A), the total number of huCD45+ cells/ml in the peripheral
blood was significantly increased from premobilization levels
following 7 days of G-CSF treatment (Figure 1B). Moreover,
the percentage of human monocytic cells (huCD45+/CD33+/
CD14+) increased from 2.6% (±0.9%) premobilization to an
average of 26.9% (±6.3%) on day 7 of mobilization (data not
shown). Total huCD33+/CD14+ cells/ml in the peripheral blood
was significantly increased from premobilization levels at days
3 and 7 of G-CSF treatment (Figure 1C). By contrast, PBS admin-
istered by osmotic pump had no effect on human PBMC popu-
lations in huCD34+ engrafted, HCMV-infected mice (data not
shown).
Following G-CSF mobilization, a notable increase in HCMV
organ dissemination was observed. All infected mice treated
with G-CSF had HCMV DNA in BM, spleen, liver, kidney, and
PBMCs (Table 1). Some HCMV-infected mice that received
G-CSF also had viral DNA in lung, bladder, and submandibular
salivary glands (Table 1). These findings suggest that G-CSF
treatment of engrafted mice resulted in the mobilization ofMicrobe 8, 284–291, September 16, 2010 ª2010 Elsevier Inc. 285
Figure 1. Mobilization of Monocytes to the Peripheral Blood in HCMV-Infected, huCD34+-Engrafted Mice with G-CSF and AMD3100
(A) Peripheral blood mononuclear cells from HCMV-infected, engrafted mice were analyzed for murine CD45 (Ly5.2), huCD45, huCD33, and huCD14 expression
by flow cytometry before and after 7 days of mobilization with either G-CSF or G-CSF + AMD3100.
(B and C) AMD3100 + G-CSF treatment resulted in an earlier and more robust mobilization of total huCD45+ PBMCs and huCD33+/huCD14+ monocytes in
comparison to G-CSF treatment alone. Total huCD45+ cells/ml (B) or huCD33+/huCD14+ cells/ml (C) of peripheral blood in HCMV-infected, engrafted mice
were determined premobilization and at days 3 and 7 of mobilization with either G-CSF or G-CSF + AMD3100 by normalizing the percent of cells positive for
huCD45 expression by flow cytometry to total white blood cell counts. Gray, , premobilized; black,, mobilized. Data represent mean ± SEM (n = 4). *p < 0.05.
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G-CSF Reactivates HCMV in Humanized Micea persistently or latently infected population of hematopoietic
cells from BM to the peripheral blood and organ tissues.
G-CSF-Induced HCMV Dissemination Correlates
with Increased Viral DNA Levels in Organ Tissues
Since G-CSF robustly mobilized monocytes in huCD34+-
engrafted mice and monocytes are the proposed vehicle of viral
spread, we hypothesized that G-CSF treatment would increase
viral DNA levels in organ tissue. To quantitatively evaluate
differences in viral DNA pre- and post-G-CSF mobilization,
real-time quantitative PCR was performed on organ tissue.
Briefly, engrafted mice were injected IP with mock-infected,
HCMV-infected, and UV-inactivated HCMV-treated fibroblasts.
HCMV-infected, nonengrafted mice were again included as an
additional negative control. G-CSF mobilization increased viral
DNA in the spleen (Figure 2A), BM (Figure 2B), and liver
(Figure 2C) of engrafted, HCMV-infected mice at 5 weeks post-
infection compared to nonmobilized HCMV-infected mice and
controls, thereby demonstrating that mobilization of hematopoi-
etic cells results in increased HCMV dissemination. The lack of
detectable HCMV DNA in UV-inactivated HCMV control mice
indicated that a live HCMV infection was required for viral spread
to occur.286 Cell Host & Microbe 8, 284–291, September 16, 2010 ª2010 ElsEnhanced Hematopoietic Cell Mobilization
with G-CSF and AMD3100 Results in Increased Viral
DNA Compared to G-CSF Treatment Alone
Stromal cell-derived factor-1 (SDF-1), which is constitutively
expressed in BM, is essential for the retention of undifferentiated
HSCswithin the BM (Aiuti et al., 1997;Ma et al., 1999; Shen et al.,
2001). Inhibition of the SDF-1 receptor CXCR4 with the CXCR4
antagonist AMD3100 increases hematopoietic stem cell mobili-
zation in humans (Broxmeyer et al., 2005) and in NOD/SCIDmice
(Pitchford et al., 2009), particularly when administered with
G-CSF(Flomenberg et al., 2005). To further demonstrate the
link between hematopoietic cell mobilization and increased
HCMV spread, we treated engrafted, HCMV-infected mice with
G-CSF alone and G-CSF + AMD3100 via osmotic pump for
7 days at 4 weeks postinfection. Although at day 7 of treatment,
all mobilized mice had similar ratios of mouse and human CD45+
cells and a similar percentage of huCD33+/CD14+ cells (Fig-
ure 1A), we observed a significant increase in total huCD45+
cells/ml (Figure 1B) and huCD33+/CD14+ cells/ml (Figure 1C)
after 3 days of mobilization in G-CSF + AMD3100-treated mice
compared to G-CSF-treated mice. The earlier kinetics of
hematopoietic cell mobilization seen with G-CSF + AMD3100
correlated with a greater than 2-fold increase in viral DNAevier Inc.
Figure 2. HSC Mobilization Increases Viral Genomic DNA in Organ Tissues of huCD34+-Engrafted Mice Infected with HCMV
(A–C) G-CSF treatment of HCMV-infected engrafted mice for 7 days results in increased HCMV genomic DNA in spleen (A), bone marrow mononuclear cells (B),
and liver (C). Engrafted mice were injected IP with mock-infected fibroblasts (engrafted mock), UV-inactivated HCMV-treated fibroblasts (engrafted UV-HCMV),
or HCMV-infected fibroblasts (engrafted HCMV). At 4 weeks postinfection, engrafted mice were treated with G-CSF (+ G-CSF) for 7 days or left untreated
( G-CSF) and sacrificed. As an additional negative control, nonengrafted mice were injected IP with HCMV-infected fibroblasts, treated with G-CSF for
7 days at 4 weeks postinfection, and sacrificed (nonengrafted HCMV + G-CSF). Total DNA was harvested from organ tissue and analyzed for HCMV genomic
DNA by quantitative real time PCR. Data represent mean copies/mg ± SD (n = 5). *p < 0.05.
(D) Enhanced HSC mobilization with AMD3100 + G-CSF correlates with a further increase in HCMV viral load in liver. HCMV-infected engrafted mice were
administered PBS, G-CSF, or AMD3100 + G-CSF for 7 days and sacrificed. Total DNA was isolated from liver and analyzed by quantitative real-time PCR for
HCMV genomic DNA. Data represent mean copies/mg ± SD (n = 3, HCMV + PBS; n = 4, HCMV + G-CSF, HCMV + G-CSF + AMD3100). *p < 0.05.
Cell Host & Microbe
G-CSF Reactivates HCMV in Humanized Micein the liver compared to G-CSF treatment alone (Figure 2D).
Altogether, these data demonstrate a direct link between
increased mobilization of myeloid lineage cells from the BM
and increased viral load in organ tissue.
Hematopoietic Cell Mobilization Results in Increased
HCMV Gene Expression and Antigen Expression
in Human Tissue Macrophages
To determine if G-CSF-mediated viral spread correlated with
increased viral mRNA expression, quantitative RT-PCR was
performed on liver RNA isolated from PBS-treated and G-CSF-
treated HCMV-infected mice at 2 weeks posttreatment. Tran-
scripts for the late HCMV glycoprotein B (gB; UL55), the early
HCMV tegument protein pp65 (UL83), and the viral-encoded
CXC chemokine UL146 were detectable in all 5 G-CSF-mobi-
lized mice and absent in the three PBS-treated control mice
(Figure 3A). Furthermore, viral DNA increased in liver tissue of
infected mice in comparison to PBS-treated control mice (Fig-
ure 3C). The detection of early and late HCMVmRNA expression
in the liver of G-CSF-treated mice demonstrated that G-CSF-
mobilized hematopoietic cells were permissive for HCMVCell Host &replication and would likely contribute to viral spread in a fully
permissive human host. BM mononuclear cells isolated from
mobilized and nonmobilized HCMV-infected mice were also
negative for all three transcripts (Figure 3A) despite the presence
of viral DNA (Figure 3B), suggesting that viral reactivation occurs
during the migration of infected cells to organ tissue.
Since we observed a robust mobilization of huCD33+/CD14+
monocytes in the peripheral blood (Figure 1), we hypothesized
that monocytes/macrophages would be the primary site of
HCMV persistence. Therefore, we evaluated the expression
of viral antigens by tissue-resident macrophages in the liver
of these mice by immunofluorescence staining. Sections of
liver were stained with mAbs against huCD14 and huHLA-DR
in conjunction with a polyclonal Ab cocktail against the late
HCMV glycoproteins gB and gH. HCMV gB and gH staining
was seen in all HCMV-infected animals examined, while mock-
infected mice and those mice receiving fibroblasts infected
with UV-inactivated HCMV had no detectable gB and gH antigen
expression (Figure 3D). Furthermore, all cells expressing gB and
gH in infected mice also expressed huCD14 and huHLA-DR,
indicating that cells permissive for HCMV replication are humanMicrobe 8, 284–291, September 16, 2010 ª2010 Elsevier Inc. 287
Figure 3. HCMVPermissively Infects Mono-
cytes/Macrophages in huCD34+ -Engrafted
Mice
(A) HCMV mRNAs are expressed in liver following
HSC mobilization. Engrafted mice were infected
with HCMV, treated with G-CSF (n = 5) or PBS
(n = 3) for 7 days at 4 weeks postinfection, and
sacrificed at 6 weeks postinfection. Levels of
UL55 (gB, gray ,), UL83 (pp65, black ,), and
UL146 (white ,) mRNAs were quantified by
real-time PCR of total liver and bone marrow
mononuclear cell mRNA. PBS AVG Liver, PBS
AVG BM, and G-CSF AVG BM represent the
mean values of transcripts for PBS-treated mouse
liver tissue, PBS-treated mouse bone marrow
mononuclear cells, and G-CSF-treated mouse
bone marrow mononuclear cells, respectively.
(B and C) HCMV genomic DNA is present in
the bone marrow of G-CSF-mobilized and
PBS-treated mice (B) and increases in the liver of
HCMV-infected engrafted mice following G-CSF
treatment (C). Engrafted mice were infected with
HCMV, treated with G-CSF (n = 5) or PBS (n = 3)
for 7 days at 4 weeks postinfection, and sacrificed
at 6 weeks postinfection. Total DNA was har-
vested from organ tissue and analyzed for HCMV
genomic DNA by quantitative real time PCR.
Data represent mean copies/mg ± SD (n = 5).
*p < 0.01.
(D) HCMV gB/gH expression is limited to
CD14+ HLA-DR+ monocytes. Engrafted mice
were injected IP with HCMV-infected fibroblasts,
UV-inactivated HCMV-treated fibroblasts, or
mock-infected fibroblasts. At 4 weeks postinfec-
tion, mice were administered G-CSF for 7 days
and sacrificed. Liver tissue sections were stained
with antibodies against huCD14, huHLA-DR, and
HCMV gB/gH. Four-color immunofluorescence
images of 8 mm liver cryosections were obtained
for Hoechst-stained nuclei (blue; all panels),
huCD14 (green; left), huHLA-DR (red; middle),
and HCMV gB/gH (purple; right). HLA-DR+CD14+
monocytes coexpressing HCMV gB and gH were
seen only in HCMV-infected mice treated with
G-CSF. Scale bars = 25 mm.
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binations were also examined. Cells coexpressing the HCMV
immediate early-1 (IE-1) protein and pp65 were detected in
liver sections of HCMV-infected, G-CSF-treated mice, but not
in HCMV-infected, non-G-CSF-treated mice (Figure S1). Fur-
thermore, IE-1 was only detected in cells positive for a human-
specific nuclear antigen (Figure S1). Altogether, these data
demonstrate that viral antigen expression is limited to human
monocyte/macrophages.
DISCUSSION
In summary, we have shown that huCD34+-engrafted NOD-scid
IL2Rgc
null mice infected with HCMV can support a latent
viral infection that reactivates in macrophages following
G-CSF-induced mobilization of bone-marrow hematopoietic
cells. In addition, cotreatment of latently infected mice with
AMD3100 (Plerixafor) and G-CSF significantly increased HCMV
load in these animals in comparison to G-CSF alone. Our study
provides a humanizedmousemodel that can be used to examine
mechanisms of HCMV latency and reactivation. To date, the
most commonly used humanized model for HCMV involves the
implantation of a human fetal conjoint thymus/liver implant under
the kidney capsule of SCID mice (Bidanset et al., 2001, 2004;
Mocarski et al., 1993). This SCID-hu model provides a limited
reconstitution of human hematopoietic cells, with an average
of 0.7% huCD45+ cells in the peripheral blood 3–5 months
posttransplantation (Legrand et al., 2006). The human PBMCs
are almost exclusively of T cell origin in this model, although
myeloid lineage cells are contained within the engrafted tissue
(Legrand et al., 2006). While this HCMV SCID-hu model does
support replication in epithelial cells of the thymic medulla,
HCMV does not infect myeloid lineage cells within the implant
and does not spread systemically within the mouse (Mocarski
et al., 1993). In contrast, the huCD34+ engrafted NOD-scid
IL2Rgc
null mouse model provides significantly higher engraft-
ment of human hematopoietic cells, with an average of 52%
huCD45+ cells in the peripheral blood at 5 weeks postengraft-
ment. Furthermore, huCD34+-engrafted NOD-scid IL2Rgc
null
mice provide long-term and systemic repopulation of multiline-
age human myeloid and lymphoid cell populations (Legrand
et al., 2006). We have demonstrated that the superior engraft-
ment and repopulation of human hematopoietic lineage cells
in this mouse model support both a latent HCMV infection
in the bone marrow and a systemic reactivation of virus in
macrophages following GCSF treatment. Thus, the huCD34+-
engrafted NOD-scid IL2Rgc
nullmouse model represents a signif-
icant advancement over the previously utilized SCID-hu model.
Importantly, our studies indicate that G-CSF is a trigger for the
reactivation and dissemination of HCMV in myeloid cells to
various tissues in the host. These observations may explain
the increase in HCMV disease in patients who receive G-CSF-
mobilized blood products (Anderson et al., 2003; Meyer-Koenig
et al., 2004; Nichols et al., 2002). Specifically, G-CSF-mobilized
myeloid precursors and monocytes from donors may be primed
for HCMV replication and may pose an elevated risk for HCMV
transmission to G-CSF-mobilized blood product recipients.
Future studies will compare HCMV transmission between mice
receiving SCT with either bone marrow or G-CSF-mobilizedCell Host &stem cells from huCD34+ engrafted NOD-scid IL2Rgc
null mice.
Lastly, this HCMV mouse model will provide a valuable tool to
examine mechanisms of HCMV latency and reactivation and
will be a platform to test HCMV antiviral therapies.EXPERIMENTAL PROCEDURES
Preparation of HCMV-Infected Fibroblasts
Neonatal normal human dermal fibroblasts (NHDF) were cultured in minimum
essential media (MEM; Cellgro) supplemented with 10% fetal bovine serum at
37C with 5% CO2. NHDF were infected with low passage clinical HCMV
isolate TRpM1A at a multiplicity of infection (M.O.I.) of 3. Mock infection was
performed by addition of an equivalent volume of MEM. UV-inactivated
HCMV (UV-HCMV) was prepared as previously described (Smith et al.,
2004a) and used to treat fibroblasts at equivalent M.O.I. of 3. UV-inactivated
HCMV was replication defective as determined by plaque assay.Engraftment and Infection of NOD/SCID Mice
Seven to ten-week-old NOD-scid IL2Rgc
null mice were sublethally irradiated
(250 cGy by 137Cs g-irradiation) and engrafted with 150,000 human CD34+
cord blood cells (StemCell Technologies, Inc.; Vancouver, BC, Canada) via
retro-orbital injection. Mice were maintained in an SPF facility according to
procedures approved by the Institutional Animal Care and Use Committee of
the OHSU. At 4 weeks postengraftment, mice were injected IP with 1 3 106
NHDF that had been HCMV-infected, mock-infected, or UV-HCMV-treated.
At 4 weeks postinfection, hematopoietic cells were mobilized by administering
100 ml G-CSF (300 mg/ml; Amgen) or G-CSF + AMD3100 (5 mg/kg) for 7 days
via a subcutaneous micro-osmotic pump (1007D; Alzet).Nested PCR Analysis of HCMV Genomic DNA
DNA was isolated from 0.8 g of mouse tissues using the DNAzol method
(Life Technologies). As described previously (So¨derberg et al., 1993),
a 332 bp region of the HCMV genome was amplified by nested PCR using
HCMV-specific forward and reverse primers for exons 1 and 2 of the major
immediate early (MIE) gene. The outer primer pairs used were 50-GAGTCC
TCTGCCAAGAGAAA-30 and 50-GAGTTCTGCCAGGACATCTTT-30, and the
inner primer pairs were 50-GAGTTCTGCCAGGACATCTTT-30 and 50-CTCGG
GGTTCTCGTTGCAAT-30. The outer primer pair PCR reaction mixture (20 ml)
consisted of 100 ng DNA, 1x ThermoPol buffer (New England BioLabs),
200 mM each deoxynucleoside triphosphate (DNTP), 1 mM of each primer,
and 0.2 ml of vent DNA polymerase (New England BioLabs). Thirty cycles of
outer primer PCR were performed, with each cycle consisting of denaturation
(20 s at 94C), annealing (50 s at 62C), and extension (20 s at 72C). For the
inner primer pair PCR reactions, the same reaction mixture was utilized with
2 ml of the outer primer pair PCR reaction diluted 1:100. Thirty cycles of inner
primer PCR were performed, consisting of denaturation (20 s at 94C) and
combined annealing and extension steps (1 min at 60C). Southern blot
analysis was performed on PCR products using a MIE-specific 32P-30-
end labeled oligonucleotide probe (50-ATATCTCCTGTATGTGACCC-30).
All nested PCR results were confirmed with a second independent nested
PCR reaction.Flow Cytometry
Peripheral blood from host mice was erythrocyte depleted by sedimentation
in 3% dextran (Amersham Pharmacia, Sweden) followed by hypotonic
lysis. Bone marrow from host mice was obtained by flushing tibia and
femora. Human hematopoietic engraftment was analyzed with antibodies
(all from BD) to human CD45 conjugated to allophycocyanin (APC), mouse
CD45.1-fluorescein isothiocyanate (FITC), and the lineage markers CD33-
phycoerythrin (PE), CD14-Pacific Blue, CD3-PE, CD4-APC-H7, CD8-FITC,
and CD19-PE. Dead cells were excluded by a combination of scatter gates
and propidium iodide staining. Cells were analyzed on a BD LSRII (BD Biosci-
ences) and data were analyzed using FCS express V3 (De Novo; Los Angeles,
CA). Complete circulating blood analysis of peripheral bloodwas performed by
IDEXX Laboratories (Westbrook, ME).Microbe 8, 284–291, September 16, 2010 ª2010 Elsevier Inc. 289
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DNA was extracted from 0.8 g of mouse tissues (liver, spleen, and bone
marrow) using the DNAzol method (Life Technologies). A total of 1 mg of
DNA was analyzed by TaqMan PCR techniques using a probe/primer set
recognizing a HCMV UL146 sequence. Primers used were UL146 Forward
(50-CCGCCTGGACATGGAGTATG-30) and UL146 Reverse (50-GTCTCGG
TTCTGGTGATTTCG-30 ). The probe used was 50-TTATCGCCCGATCACC-30
labeled on the 50 end with the reporter FAM and on the 30 end with a non-fluo-
rescent quencher (Applied Biosystems, Foster City, CA). PCR reactions were
set up using the TaqMan Universal PCR Master Mix (Applied Biosystems)
according to the manufacturer’s specifications. Following thermal activation
of AmpliTaq Gold (10 min. at 95C), a total of 40 cycles were performed
(15 s. at 95C and 1 min. at 60C) using StepOne-plus TaqMan apparatus
(Applied Biosystems). DNA isolated from sucrose gradient purified HCMV
was used to determine the standard curve. TaqMan results were analyzed
using ABI StepOne Real-Time software. The sensitivity of detection for this
assay was <50 copies.
Quantitative RT-PCR Detection of HCMV Gene Expression
RNA was extracted from 0.8 g of liver tissue using the TRIzol reagent
(Invitrogen) and following the manufacturer’s protocol. cDNA was synthesized
from 1 mg of total RNA using 1.0 mM oligo dT primer (oligo dT12-18) and 200 U
Superscript III reverse transcriptase (Invitrogen). Primer and probe sets were
identified using Primer Express software (Applied Biosystems). The primers
and probe sequences used were UL55 P1 (50-CCGTCCGTCCAAAGAA
TCTG-30), UL55 P2 (50-TTACACCAACGAGCAGGCTTAC-30 ), UL55 probe (50-T
GCTGCGCTCGCT-30), UL83 P1 (50-TGGAGAACGTGTCGGTCAAC-30), UL83
P2 (50-GGATGTTCAGCATCTTGAGCG-30), UL83 probe (50-AGCCAGGAGCC
CATGTCGATCTATGTGTAC-30), UL146 P1 (50-CCGCCTGGACATGGAGTA
TG-30), UL146 P2 (50-GTCTCGGTTCTGGTGATTTCG-30 ), and UL146 probe
(50-TTATCGCCCGATCACC-30). PRT-PCR reactions were performed using
specific TaqMan probes and Master Mix (Applied Biosystems). Following
thermal activation of AmpliTaq Gold (10 min at 95C), a total of 40 cycles
was performed (15 s at 95C and 1 min at 60C) using the ABI Prism Step
One Plus Sequence Detection System (Applied Biosystems). Plasmid clones
containing each gene fragment were used as positive controls and quantifica-
tion standards. PCR results were analyzed using ABI Prism Step One
Sequence Detection Software. The sensitivity of detection of this assay
was <100 plasmid copies for all the tested HCMV genes.
Immunohistochemistry
Livers were frozen in O.C.T. compound (Tissue-Tek). Cryostat sections of 7 mm
were fixed in Streck Tissue Fixative (Streck Laboratories) for 30 min. Antigen
retrieval was performed with ficin (Digest-All 1 kit; Zymed) for 15 min at
37C. Sections were blocked with 10% normal rabbit serum and 10% normal
goat serum for 30min. Primary antibodies against huCD14 (mousemAb; clone
UCHM-1; Sigma-Aldrich), huHLA-DR (rabbit mAb; ab52478; Abcam), and
HCMV gB/gH (goat polyclonal antibody; 0801; ViroStat) were incubated for
1 hr. Sections were stained with secondary antibodies (Alexa fluor 488 F
(ab0)2 goat anti-mouse IgG, Alexa fluor 594 F(ab0)2 anti-goat IgG, Alexa fluor
647 F(ab0 )2 goat anti-rabbit IgG; Molecular Probes) for 1 hr. Slides were stained
with Hoechst for 10 min. All primary antibodies were preabsorbed against
mouse liver powder (Rockland), and all primary and secondary antibodies
tested negative for background staining on nonengrafted mouse liver tissue
sections.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
article online at doi:10.1016/j.chom.2010.08.001.
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